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Hereditary breast cancer comprises ~7% of the annual breast cancer cases in the United 
States. The two genes suspected in the majority of cases are the breast and ovarian cancer 
susceptibility genes 1 and 2 (BRCA1 and BRCA2). Although BRCA genetic testing has 
aided in the identification of specific individuals at risk for breast and ovarian cancer, the 
large number of BRCA variants of unknown clinical significance (VUS) continues to 
complicate prevention strategies. To augment the ongoing VUS classification effort, two 
novel approaches for studying BRCA VUS were developed. First, an isogenic panel of 
immortalized human breast cells harboring eight different clinically reported BRCA1 
alleles were established to study genomic instability. Consistent with previous findings, 
cells harboring a deleterious allele (185delAG, C61G and R71G) demonstrate increased 
ɣ-irradiation sensitivity and genomic instability, as measured by fluorescent in situ 
hybridization. Interestingly, not all deleterious alleles demonstrated the same level of 
haploinsufficiency, as each genotype exhibited varying degrees of change from the 
control cell lines across different assays. Second, an improved approach for studying 
BRCA variant loss-of-heterozygosity (LOH) within archival tumor tissue was developed. 
Using a new digital PCR platform, droplet digital PCR (ddPCR), BRCA2 LOH was 
assessed in formalin fixed paraffin embedded (FFPE) tissues for two related breast cancer 
patients harboring a rare missense BRCA2 variant of unknown clinical significance 
(c.6966G>T; M2322I). Conventional PCR followed by Sanger sequencing suggested a 
change in allelic abundance in the FFPE specimens. However, there was no evidence of 
LOH as determined by the allelic ratio (wild type:variant) for BRCA2 in both patients’ 
archival tumor specimens and adjacent normal control tissues using ddPCR. In summary, 
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these experiments demonstrate two novel approaches for studying the clinical 
significance of uncertain BRCA alleles. 
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Discovery of BRCA1 & BRCA2  
Breast cancer is caused by the accumulation of somatic mutations in the DNA of 
mammary epithelial cells (1). Although the majority of cancers are sporadic, caused by 
spontaneous DNA mutations, a subset of annual cases are linked to the transmission of 
susceptibility factors (2). Yet, decades before the discovery of the genes responsible for 
causing familial breast cancer, clinicians made several observations that aided in their 
discovery. Physicians noted that for some individuals, breast cancer onset was 
remarkably early in life and often these individuals had a higher incidence of multiple 
primary tumors. Additionally, these patients routinely had extensive family histories of 
cancer, sometimes including male breast cancers (3). Utilizing these important features to 
identify suspect families, investigators eventually identified the principal genes 
responsible for influencing hereditary breast cancer onset (4). It is now commonly 
accepted that the two major genes responsible for predisposing individuals to breast and 
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ovarian cancer are BRCA1 and BRCA2, both of which were cloned in the mid-1990s. 
Other lower frequency genes known to influence familial breast cancer susceptibility, 
including PTEN, CDH1, ATM, CHEK2, PALB2 and STK11 are reviewed elsewhere (2). 
 In 1990, BRCA1 was first mapped to human chromosome 17q using linkage 
analysis in a series of 23 large kindreds with the archetypal breast cancer family history 
(5). At the time, it was hypothesized that BRCA1 was an autosomal dominant tumor 
suppressor gene, and therefore, should follow the classical two hit hypothesis previously 
described by Alfred Knudson (6). Consistent with the theory, somatic allelic losses were 
predicted to occur at 17q at some frequency in both hereditary and sporadic tumors. 
Indeed, shortly after the localization of BRCA1 to 17q, researchers published reports 
demonstrating genomic losses on 17q in both sporadic and familial breast cancer (7, 8). It 
was not until several years later, after laborious effort, was the BRCA1 gene finally 
isolated using positional cloning (9). Again, consistent with the contemporary notion that 
BRCA1 was a tumor suppressor gene and should follow the two hit hypothesis (6), 
somatic loss of the remaining wild-type allele was observed in the tumors of patients 
harboring germ line BRCA1 mutations. Paradoxically, however, somatic mutations 
resulting in complete loss of function of BRCA1 were rarely observed in sporadic breast 
cancers (10). This led researchers to speculate that other mechanisms for reducing 
BRCA1 expression may be involved, such as epigenetic gene silencing through 
methylation of the BRCA1 promoter (11).  
 Notably, germ line BRCA1 mutations were not observed in purported cancer 
families with male breast cancer (12) and BRCA1 did not seem to account for all families 
displaying an autosomal dominant pattern of breast and ovarian cancer inheritance. These 
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observations led investigators to search for other causative genes culminating in the 
localization of BRCA2 to human chromosome 13q in 1994 (13) and ultimately its 
identification a year later (14). Similar to the genetics of BRCA1, and again consistent 
with being a tumor suppressor gene, somatic loss of the remaining wild-type BRCA2 
allele was observed in a significant number of patient tumors with a germ line BRCA2 
mutation (15). In contrast to BRCA1, however, transmission of a deleterious BRCA2 
allele also appears to increase the risk of developing cancers outside the breast and 
ovaries, particularly cancers of the pancreas and prostate (16, 17). Additionally, certain 
germ line homozygous mutations in BRCA2 cause the rare autosomal recessive disease, 
Fanconi anemia (18). 
Soon after the discovery of the BRCA genes it became apparent that both were 
highly polymorphic. Therefore, to manage the growing number of discovered germ line 
BRCA alleles and bolster research efforts, the Breast Cancer Information Core (BIC) was 
established in 1995 (19). As of the writing of this thesis, the BIC catalogs >1,800 unique 
BRCA1 alleles and >2,000 BRCA2 alleles. Within the BIC three types of clinical 
designations exist for the cataloged alleles: deleterious, benign and unknown variant. 
Deleterious alleles comprise ~50% and ~41% of the cataloged BRCA1 and BRCA2 alleles, 
respectively. Most of the deleterious alleles are the result of frame-shift or truncating 
mutations, having obvious adverse effects on the translated protein products. 
Unfortunately, ~48% and ~56% of the cataloged BRCA1 and BRCA2 alleles, respectively, 
are considered variants of unknown clinical significance (VUS). Most VUS are 
comprised of missense, intronic and regulatory region mutations with unclear phenotypic 
consequences. The existence of the large number of VUS has catalyzed many research 
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efforts aimed at determining their clinical significance and are discussed in more detail 
below. 
Gene Structure & Protein Domains 
In addition to being highly polymorphic, both BRCA1 and BRCA2 are very large genes, 
encoding very large proteins. Several BRCA1 isoforms have been reported to exist within 
cells. The most commonly studied isoform spans 23 exons and encodes a protein 1,863 
amino acids in size (~220 kD), located predominately within the nucleus (9, 20). A splice 
variant arising from the same transcript, but lacking the majority of exon 11 has also been 
reported (~110 kD) (21). This isoform, termed BRCA1-Δ11b, accumulates in the 
cytoplasm because it lacks its exon 11 encoded nuclear localization signals. A decade ago, 
another group published a report claiming the existence of a unique functionally 
important isoform, termed BRCA1-IRIS, resulting from an uninterrupted reading frame 
starting from exon 1 extending into intron 11 (22). In spite of multiple BRCA1 isoform 
reports, the majority of studies to date focus on the 220 kD BRCA1 (p220) protein. 
Therefore, any mention here of the BRCA1 protein refers to the p220 isoform, unless 
otherwise stated.  
 Two important, evolutionarily conserved functional domains exist within 
BRCA1: the N-terminal RING motif and the C-terminal tandem BRCT motifs. Both 
domains appear to be essential for BRCA1 mediated tumor suppression, as known cancer 
causing mutations have been identified in each (9, 23–25). Interestingly, the BRCA1 C-
Terminal (BRCT) domain was originally identified through a bioinformatics approach 
(26). Using protein BLAST, Koonin et al. reported that two other nuclear proteins, 
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53BP1 and RAD9, share what appeared to be a conserved protein domain, which they 
named after BRCA1. Using an alternative sequence analysis approach, hydrophobic 
cluster analysis, another group subsequently identified several other nuclear proteins 
possessing BRCT domains (27). Present data support the notion that at least for certain 
BRCT superfamily members, including BRCA1, the BRCT domain acts as a 
phosphopeptide binding module important for mediating the DNA damage response (28, 
29). Currently, over two-dozen proteins harboring a BRCT domain have been identified 
with most having some role in either cell cycle checkpoint control and/or the DNA 
damage repair response (30, 31). 
 The other well studied BRCA1 motif, the N-terminal zinc finger RING domain, 
was also originally identified by querying a contemporary sequence database (9, 32). 
RING domains are one of two major types of domains found in the superfamily of E3 
ubiquitin ligases. Perhaps not surprisingly, BRCA1’s RING domain is important for 
mediating its confirmed E3 ubiquitin ligase activity (33–35). In addition, BRCA1’s 
RING domain mediates heterodimer formation with its binding partner, BARD1 (36). 
The importance of BRCA1/BARD1 heterodimer formation is underscored by the 
presence of known cancer causing mutations located within the RING domain, disrupting 
normal tertiary structure necessary for interaction between the two proteins (37). 
Heterodimer formation enhances BRCA1’s E3 ligase activity (33, 34) and appears to be 
mutually important for each protein’s stability within cells (38). Although the RING 
domain appears to be required for tumor suppression (39), it remains controversial 
whether BRCA1’s ubiquitin ligase activity is required for tumor suppression in humans, 
as conflicting data currently exists (40–42). 
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 Distinct from BRCA1, the BRCA2 gene located on the long arm of human 
chromosome 13 spans 27 exons encoding a protein 3,418 amino acids in size (380 kD) 
(43). Their appears to be only one BRCA2 isoform and it is found predominately within 
the nucleus (44). Currently, only two corroborated functional domains have been 
described for BRCA2: the evolutionarily conserved eight BRC repeat motifs encoded 
within exon 11 and the C-terminal domain that harbors its nuclear localization signals. 
Similar to cancer mutations found in the two conserved functional domains of BRCA1, 
known cancer causing mutations are found in the two important functional domains of 
BRCA2, again underscoring their importance for normal BRCA2 tumor suppressor 
function (45, 46). 
Function 
BRCA1 appears to be a pleiotropic mammalian gene with multiple functions now 
ascribed to its gene products. BRCA1 has been implicated in transcriptional regulation 
(47, 48), DNA repair (49, 50), cell-cycle checkpoint control (51, 52), centrosome 
dynamics (53–56) and epigenetic regulation (41, 57). In fact, the complete cellular 
function of BRCA1 remains an area of continued research. Therefore, for clarity, only 
BRCA1’s established role in maintaining genome integrity will be discussed further. 
More specifically, BRCA1’s critical role in maintaining genomic stability through both 
regulation of centrosome duplication and its multi-faceted role in the DNA damage 
response and repair pathway will be discussed.  
 The earliest indication that BRCA1 may play a critical role in cells came through 
knock-out mice studies evaluating different BRCA1 genotypes. Initially, researchers 
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observed that homozygous germ-line disruption of BRCA1 was incompatible with normal 
murine development and led to embryonic lethality (58–60). Interestingly, the different 
BRCA1 functional domains that were disrupted in each of these transgenic studies led to 
temporal differences in developmental termination, suggesting BRCA1 may harbor 
distinct functional domains critical at different stages of normal murine development. At 
the time, these findings seemed somewhat paradoxical since many believed that BRCA1 
loss of function would be permissive as it is frequently observed in BRCA1-associated 
tumorigenesis. It is important to note, however, that none of the monogenic knock-out 
mice studies to date have observed any increase in mammary tumor incidence for 
BRCA1
+/-
 heterozygous mice. This may be due to the inherently shorter lifespan of mice 
and/or the limited follow up time within these studies. An alternative explanation is that 
important species-specific differences exist between humans and mice. Consistent with 
this theory, there appear to be no observable phenotypes associated in murine BRCA1
+/-
 
heterozygous mammary cells, contrasting to the reports claiming that BRCA1 
haploinsufficiency may exist in certain human tissues (61–64). Is biallelic inactivation of 
BRCA1 embryonic lethal for humans as well? As of this writing, there appear to be only 
two publications to date reporting the presence of individuals with germ line homozygous 
BRCA1 deleterious mutations (65, 66). The first article reporting a women with a 
homozygous BRCA1 founder mutation (c.2800delAA) has since been refuted, as it seems 
the author’s genotypic conclusions were based on the result of a PCR artifact (65, 67, 68). 
The second article, published recently, describes a cancer affected women harboring one 
deleterious allele (c.2457delC) and one VUS allele (V1736A) (66). The proband was 
diagnosed at age 28 years with stage IV papillary serous ovarian carcinoma, and she had 
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a clinical history of both microcephaly and short stature. In their report, the authors 
provide strong evidence that the VUS may be a hypomorphic allele. Therefore, until 
proven otherwise, it seems that complete loss of BRCA1 function is incompatible with 
normal human embryogenesis as well.  
BRCA1’s role in the repair of DNA double strand breaks has been extensively 
studied (49). Early evidence for this function arose from studies of BRCA1’s unique 
nuclear staining pattern, and BRCA1 was found to co-immunoprecipitate with the DNA 
recombination factor, RAD51 (69). BRCA1’s suspected role in DNA repair was quickly 
confirmed by the observation that mouse embryonic stem cells lacking BRCA1 were 
deficient in DNA repair by homologous recombination (49). Bolstering this finding, 
another group found that exogenous expression of wild-type BRCA1 suppressed 
radiation hypersensitivity using a newly established human cancer cell line derived from 
a BRCA1 deleterious mutation carrier (70, 71). The cancer cell line (HCC1937) utilized 
in this study lacked normal BRCA1 function resulting from the presence of a germ line 
BRCA1 mutation (5382insC) with loss of the remaining wild-type allele. Since these 
groundbreaking discoveries, a vast amount of work has been carried out corroborating 
BRCA1’s role in the repair of DNA damage. Subsequent reports suggest that BRCA1 is 
found in several DNA repair protein complexes involved in the homology mediated 
repair of different types of DNA lesions, including collapsed replication forks and cross-
linked DNA (50, 72, 73).  
The other established genome-maintaining function of BRCA1 is its regulatory 
role in centrosome dynamics. Insight into this function was also initially gleaned from 
studies of isolated BRCA1 null fibroblasts from embryos of BRCA1 homozygous knock-
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out mice (53). In the study by Xu et al., significant genetic instability in the BRCA1 
deficient cells was observed, which appeared to be linked, at least in part, to centrosome 
duplication and a defective G2-M cell cycle checkpoint. At the time, hypothesizing that 
BRCA1 may somehow regulate centrosome dynamics seemed plausible, as previous 
immunofluorescence work suggested that BRCA1 localized to the centrosome and 
interacted with ɣ-tubulin (54). Similar to BRCA1 research focusing on DNA damage 
repair, over a decade has passed since these initial reports linking BRCA1 to centrosome 
dynamics with a more complete picture now existing. Briefly, the current model for 
BRCA1 mediated centrosome regulation stipulates that in a cell-cycle dependent manner, 
the BRCA1/BARD1 heterodimer ubiquitinates ɣ-tubulin preventing secondary 
centrosome duplication (55, 56, 74). Upon BRCA1 loss of function, cells are found to 
have supernumerary centrosomes, which promote genomic instability.   
 BRCA2’s function within cells seems to be primarily restricted to the repair of 
DNA double strand breaks (44). Not surprisingly, the earliest evidence for BRCA2’s role 
in DNA repair also arose through knock-out mice studies. Like BRCA1 deficient mice, 
nullizygosity for BRCA2 leads to murine embryonic lethality (75). Sharan et al., 
demonstrated that BRCA2 null cells both show a marked sensitivity to ɣ-irradiation and 
that BRCA2 interacts with RAD51 via its BRC repeat domain. Yet BRCA2’s direct role 
in DNA repair by homologous recombination was not confirmed until several years later 
by Moynahan et al. (76). In summary, a great number of reports have been published 
corroborating BRCA2’s role in mediating the repair of DNA double strand breaks via 





BRCA-linked breast cancers, in contrast to sporadic breast cancers, exhibit distinct 
pathological characteristics. Collectively, BRCA1-linked disease tends to be higher grade 
at diagnosis with an increased number of observable mitoses compared to both BRCA2-
linked and sporadic disease (79, 80). Approximately 70% of the BRCA1 associated 
tumors do not express any of the three commonly scored breast cancer receptors 
(estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor 
receptor 2[HER2]), designating them as ‘triple negative’ (81). Moreover, BRCA1 tumors 
often express several cytokeratins classifying them as of the ‘basal-like’ gene expression 
subtype as well (82). In contrast to BRCA1, a majority of BRCA2 tumors are often ER 
positive and less aggressive (81). Interestingly, the distribution and frequency of TP53 
mutations seems to be distinct within BRCA tumors. Indeed, not only do TP53 mutations 
seem to be more common within BRCA related tumors, as compared to sporadic cases, 
truncating mutations within TP53 seem to be favored over missense mutations (83–86). 
 Penetrance for BRCA-linked disease appears to vary widely (87–89). This is likely 
due to environmental effects, the influence of modifier genes and the highly polymorphic 
nature of the BRCA genes. Now, twenty years following the discovery of BRCA1/2 and 
despite the large number of published reports, disease penetrance estimates remain a 
matter of debate (90). However, it is commonly accepted that for BRCA1 carriers, the 
lifetime risk of breast cancer is approximately 60-70% and 20-40% for ovarian cancer. In 
addition, it is commonly accepted that BRCA2 linked disease has reduced penetrance 
relative to BRCA1 with estimates ranging from 40-60% for breast cancer and 10-20% for 
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ovarian cancer (91). The accepted median age at diagnosis for deleterious carriers is 40 
and 43 years for BRCA1 and BRCA2, respectively (81). 
Not surprisingly, BRCA genetic testing has become an important prerequisite for 
disease prevention (92). To identify carriers of deleterious BRCA alleles, individuals 
demonstrating risk criteria (i.e. personal and/or family history) are regularly encouraged 
by their clinicians to pursue clinical genetic counseling and testing. There are four 
possible outcomes for patients receiving BRCA genotyping: i) no mutation is found, ii) a 
benign variant is found, iii) a deleterious mutation is found, or iv) a variant of unknown 
significance (VUS) is found. Obviously, outcomes i and ii suggest the individual has no 
increased risk of BRCA-linked disease. For outcome iii, individuals may then decide to 
pursue intensive screening or preventative treatments. Broadly, the three preventative 
measures include increased screening, prophylactic surgery, and chemoprevention, with 
surgery being the most effective. In at-risk carriers, prophylactic bilateral oophorectomy 
reduces the risk of breast cancer by ~50% (93) and prophylactic bilateral mastectomy 
reduces the risk of breast cancer by ~90% for women with their ovaries intact (94). 
Women who elect for both a prophylactic oophorectomy and mastectomy have a ~95% 
risk reduction (94). Lastly, for individuals with outcome iv, the effectiveness of 
preventative action is unclear. 
Recent work exploring synthetic lethal interactions within BRCA null cells has 
resulted in the discovery of a new, highly targeted therapeutic approach for a broad array 
of cancer types, including BRCA tumors. In 2005, two groups simultaneously published 
landmark work demonstrating remarkable killing of BRCA null cells using both poly-
ADP-ribose polymerase inhibitors (PARPi) and PARP RNA interference technology (95, 
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96). It appears tumor cells with deficient homology directed DNA repair require the 
activity of PARPs (97). These findings have catalyzed a torrent of pre-clinical and 
clinical studies aimed at evaluating PARPi for an array of cancers (98–102). Indeed, 
numerous Phase I-III clinical trials aimed at assessing several different PARPi (namely, 
Rucaparib, Veliparib, Olaparib, Niraparib and Iniparib) within different cancer patient 
populations are either completed or underway (97). Relevantly, it seems PARPi therapy 
may be particularly effective for certain BRCA mutant cancers. 
Functional Approaches to Studying BRCA1 VUS 
A vast number of approaches now exist for studying the effects different DNA mutations 
have on the BRCA proteins. These methods may be partitioned into three main 
categories: multi-factorial clinically-based probabilistic modeling, in silico analysis and 
directed functional testing of the isolated BRCA protein or in vitro testing within a 
defined cellular context (103–105). The current clinical methods utilize a number of 
clinically important factors to calculate a probability that a particular VUS is deleterious, 
including: allele segregation, co-occurrence of a VUS with a deleterious allele in trans, 
pathological characteristics of tumors harboring a VUS (ER/PR/HER2 status and 
cytokeratin expression), loss-of-heterozygosity (LOH) and the presence of multiple 
primary tumors within the same individual. Arguably, the clinically based approaches are 
the most relevant in determining variant clinical significance. However, several problems 
impede their application. Particularly, a large number of VUS are extremely rare, families 
harboring said alleles are often small, and BRCA-linked disease is incompletely penetrant. 
Coupled with the high incidence of sporadic breast cancer in the general population, these 
complicating factors often lead to unreliable statistical predictions. As a result, 
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investigators have turned to directed functional approaches to augment VUS 
classification efforts. The in vitro functional approaches will be primarily discussed here, 
as they are not only relevant to this dissertation but they possess the advantage of 
interrogating full length protein within a defined cellular context.  
 Most of the in vitro studies have primarily focused on complementation of 
exogenously expressed VUS in either a cell line lacking functional BRCA or by transient 
knockdown of BRCA using RNA interference (104, 106). The earliest report of this 
approach was developed for BRCA1 by Scully et al., where it was demonstrated that 
exogenous expression of wild-type BRCA1 in the BRCA1 null cancer cell line HCC1937 
restored resistance to ɣ-irradiation (70). Using restoration of radio-resistance as a 
measure of BRCA1 function, the authors went onto to test other BRCA1 mutant/variant 
proteins, where the authors demonstrated that only functionally competent BRCA1 was 
able to restore radio-resistance. This same approach was later used by Ruffner et al. to 
study BRCA1 RING variants (33). 
 Jeffrey Parvin’s group’s has demonstrated that RNAi mediated knockdown of 
BRCA1 combined with complementation of exogenous BRCA1 cDNA can also be useful 
for studying VUS function. Using a HeLa cell line derivative harboring an integrated 
GFP reporter that measures homologous recombination (HR), Ransburgh et al. showed 
that RNAi knockdown of endogenous wild-type BRCA1 with exogenous expression of 
various BRCA1 cDNA can accurately test for VUS DNA repair function (107). Using this 
same approach in Hs578T cells, Parvin’s group went onto study the effects different 
BRCA1 VUS have on regulating centrosome duplication (108). 
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 Lastly, Shyam Sharan’s group at the NIH has employed an embryonic stem cell 
rescue approach to study BRCA VUS (109, 110). As mentioned above, BRCA 
nullizygosity is incompatible with normal development in mice. Using this observation, 
Sharan’s group developed an elegant approach to assess the ability of different BRCA 
alleles to rescue mouse embryonic stem (ES) cells from death. To accomplish this, first 
heterozygous ES cells with only one functional copy of BRCA were engineered. 
Importantly, the intact copy of BRCA was manipulated to have both a flanking HPRT1 
minigene and loxP sites, so that upon Cre mediated removal of the intact BRCA gene, the 
resultant clones would be both HAT resistant and devoid of BRCA function. Using these 
ES cell derivatives (engineered for either BRCA1 or BRCA2) they then introduced 
bacterial artificial chromosomes (BACs) harboring different BRCA VUS to assess each 
variant’s ability to rescue the clones from death.  
 This approach has subsequently been adopted by Bouwman et al. to more 
efficiently study BRCA1 VUS in a more high-throughput manner via rescue using human 
BRCA1 cDNAs, instead of BACs harboring the respective human BRCA1 VUS (111). 
Similar to Sharan’s group, Bouwman et al. created hemizygous BRCA1 mouse embryonic 
stem cells harboring a conditional BRCA1 allele. In addition, the investigators also 
utilized both alleles of the Rosa26 locus. One allele of the Rosa26 locus was engineered 
to harbor a 4-hydroxytamoxifen (4-OHT) inducible Cre, permitting Cre-mediated 
removal of the loxP flanked BRCA1 allele. And, to better control for effects due to 
random integration of the exogenous complementing BRCA1 cDNA, the investigators 
engineered the other Rosa26 allele to harbor F3 and Frt recombination sites to facilitate 
recombinase-mediated cassette exchange (111). With these improvements, the 
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As mentioned in chapter one, previous mouse studies have suggested that BRCA1-linked 
tumorigenesis may not follow the classical two-hit hypothesis outlined for tumor 
suppressor genes. Prerequisite mutations may be necessary for mammalian cells to 
tolerate bi-allelic loss of BRCA1. Therefore, to study the BRCA1 heterozygous carrier 
state, our lab previously performed somatic cell gene targeting in two non-tumorigenic 
breast epithelial cell lines: MCF-10A and an hTERT immortalized mammary epithelial 
cell line acquired from the Myles Brown lab (112, 113). In this study we chose to 
engineer cells with the most common deleterious BRCA1 mutation, the Ashkenazi 
founder mutation, BRCA1
185delAG
 (62). Using several different approaches, we found that 
the engineered cells manifested several characteristics reminiscent of the distinct features 
commonly observed in BRCA1 null cancer cells, albeit to a lesser degree. In particular, 
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our BRCA1 heterozygous cells demonstrated slowed proliferation, an altered cell-cycle 
profile, increased sensitivity to ɣ-irradiation and increased genomic instability, as 
measured using multiple approaches. To determine if these observations might mirror an 
in vivo phenotype, we also performed fluorescent in situ hybridization (FISH) 
experiments to assess genomic instability on normal breast tissue from confirmed 
deleterious BRCA carriers. Consistent with our in vitro observations, the archival tissue 
FISH results also showed an increased level of genomic copy number changes relative to 
wild-type BRCA controls. These results support the hypothesis that human breast cells 
hemizygous for BRCA1 are haploinsufficient for certain BRCA1 functions, which 
presumably accelerates tumorigenesis in deleterious carriers (114). Since this report, 
other groups have provided corroborating evidence that human breast cells may be 
haploinsufficient for certain BRCA1 functions, namely maintenance of genomic integrity 
and regulation of centrosome duplication (61, 115).  
 From these results we reasoned that we might be able to extend our isogenic 
model to study other clinically reported BRCA1 alleles for two purposes: i) develop an 
improved method for functional testing of BRCA1 VUS, and ii) determine if functional 
differences exist between known deleterious mutations (i.e. missense versus frameshift). 
If validated, such a model would possess several advantages over previously developed 
methods. For instance, previous in vitro functional approaches have either studied full-
length human BRCA1 within conditional Brca1-less embryonic mouse stem cells, 
studied exogenous expression of human BRCA1 in non-cancerous cells with knock-down 
of endogenous BRCA1 or studied exogenous expression of human BRCA1 in breast 
cancer cells deficient in BRCA1 (70, 107–109, 111). These approaches, although useful, 
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may not accurately reflect the effects different BRCA1 mutations have on protein function, 
as they are either performed outside the relevant cell type and differentiation state, and/or 
they evaluate artificial levels of BRCA1. Assuming there is an observable phenotype for 
other deleterious BRCA1 mutations (i.e. genomic instability), we posit that isogenic cell 
modeling would be an improvement over current in vitro functional approaches, since it 
would permit the study of different human BRCA1 variants within an appropriate cellular 
context (non-cancerous human breast epithelial cells) under the normal control of the 
endogenous regulatory elements. Moreover, isogenic cell modeling might provide key 
insights into the unique phenotypes associated with specific BRCA1 carrier states 
(deleterious or VUS) and the potential mechanisms that facilitate tumorigenesis amongst 
carriers.  
 For the study of VUS, we hypothesized that deleterious VUS should mimic some 
of the same features (e.g. increased ɣ-irradiation sensitivity and/or genomic instability) 
our previously derived BRCA1
185delAG 
isogenic derivatives exhibited. Similarly, benign 
VUS would be expected to behave normally in the characterization experiments. By 
applying this model, presumably, we might provide direct functional evidence to 
augment current VUS classification efforts. Secondly, we hypothesized that this approach 
might be suitable for detecting certain functional differences between distinct deleterious 
alleles. As BRCA1 is a pleiotropic gene, involved in an array of cellular functions, it is 
likely that not all deleterious mutations lead to the same level of BRCA1 functional loss 
within cells. In other words, it is possible that not all deleterious alleles lead to the same 
level of haploinsufficiency. If this hypothesis holds true, if deleterious BRCA1 alleles 
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demonstrate a spectrum of functionality, we may be able to stratify allele risk to improve 
current BRCA1-linked disease prevention strategies. 
 To test these two hypotheses, we used adeno-associated viral mediated gene 
targeting to genetically engineer a BRCA1 isogenic panel within MCF-10A cells. The 
panel members described herein include our previously characterized BRCA1
185delAG
 
clones, a pair of newly engineered hemizygous BRCA1 knock-out clones (BRCA1
Ex2-3Stop
) 
and eight new sets of missense mutations including, two deleterious alleles (C61G and 
R71G), five VUS (C64R, D67Y, L246V, S316G and Q356R) and one benign variant 
(I379M). Consistent with our previous work, we chose to evaluate each derivative’s 
relative proliferation rate, ɣ-irradiation sensitivity and genomic instability. In addition, 
we chose to evaluate centrosome number in our derivatives, as previous functional 
studies have shown that BRCA1 loss of function leads to supernumerary centrosomes 
with aberrant multipolar mitoses (53). Furthermore, recent work suggests that mammary 
cells from deleterious BRCA1 carriers may manifest BRCA1 haploinsufficiency through 
elevated centrosome number, which may also contribute to genomic instability (61). 
Materials & Methods 
Nucleic Acid Preparation 
Cell line genomic DNA (gDNA) was isolated using a QIAamp® DNA Blood Mini kit 
(Qiagen). All conventional Sanger sequencing of genomic DNA was carried out 
following PCR amplification of respective loci using Phusion® High-Fidelity DNA 
Polymerase (New England BioLabs). Preparation of cDNA derived RNA was performed 
using a First-Strand cDNA Synthesis kit (GE Healthcare). 
Cell Culture  
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The non-tumorigenic human breast epithelial cell line MCF-10A (113) and isogenic 
derivatives were grown in DMEM/F12 (1:1) media supplemented with 5% horse serum 
(Life Technologies), 20 ng/mL epidermal growth factor (Sigma-Aldrich), 10 μg/mL 
insulin (Life Technologies), 0.5 μg/mL hydrocortisone (Sigma-Aldrich), 0.1 μg/mL 
cholera toxin (Sigma-Aldrich) and 1% Penicillin-Streptomycin (Life Technologies).  
Growth Assays 
Relative cell growth rates were assessed after plating 2 x 10
3 
cells into 96-well plates and 
measuring total cellular protein using the sulforhodamine B (SRB) assay, as previously 
described (116). All chemicals used for the SRB assay were purchased from Sigma-
Aldrich. 
rAAV Construct Cloning 
Details for each of the BRCA1 alleles engineered in this study are shown in Figure 2.1A. 
All allelic prevalence numbers shown in Figure 2.1A were taken directly from Breast 
Cancer Information Core public database (updated as of January 2014), except for the 
artificial exon 2-3stop panel member. The BRCA1 exon 2-3stop mutation was engineered 
to effectively knock out one allele of BRCA1, by both deleting the splice acceptor of exon 
2 and replacing the start ATG with three stop codons in every reading frame 
(TAGaTAAcTGA). The exon 2-3stop cells and our previously described BRCA1
185delAG
 
clones (62) were used as positive controls. All genetic manipulation of the BRCA1 gene 
was carried out using distinct recombinant adeno-associated viral (rAAV) vectors for 
each of the three respective BRCA1 exons shown in Figure 2.1B. Similar to our previous 
work (117, 118), a synthetic exon promoter trapping (SEPT) gene targeting approach was 
used (schematically represented in Figure 2.2A), as previously described, since this 
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approach greatly reduces the number of background neomycin resistant clones (119). For 
brevity, the representative gene-targeting scheme shown in Figure 2.2A harbors the 
theoretical BRCA1 alteration in the 5’ homology arm, as indicated by the asterisk. The 
actual mutant arms for each of the three targeting constructs are indicated in Figure 2.2B. 
All rAAV targeting vectors were constructed by ligating the homology arm PCR products 
into an adeno-associated viral plasmid (Agilent). MCF-10A gDNA was used as PCR 
template for each BRCA1 targeting construct with all homology arm sizes shown in 
Figure 2.2B. PCR primers for homology arm construction are listed in Table 2.1. Initially, 
wildtype gene-targeting constructs were created for each of the respective loci listed in 
Figure 2.2B. Subsequently, using site-directed mutagenesis by overlap extension PCR 
(120) with Phusion® High-Fidelity DNA Polymerase (New England BioLabs), the 
wildtype targeting vectors were mutagenized to prepare each of the respective 
variant/mutant constructs listed in Figure 2.1A. Mutagenesis primers used to create each 
of the missense mutations are listed in Table 2.2. 
rAAV Production 
Infectious virus was prepared by co-transfecting HEK-293T cells (ATCC) with pHelper, 
pRC (Stratagene) and the respective BRCA1 rAAV gene targeting plasmid. 
Approximately three days post-transfection, cell-free rAAV was prepared after three 
flash freeze/thaw cycles and filtering the growth media through a 0.22 μm filter 
(Millipore).  
Gene Targeting of BRCA1 





 tissue culture flasks and incubating for 2-3 days. Following transduction the 
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cells were partitioned into fourteen 96-well culture plates in the presence of G418 (Life 
Technologies). Following G418 selection, the gDNA of the cells were systematically 
pooled and screened to identify and isolate successfully targeted ‘pre-Cre’ neomycin 
resistant clones, as previously described (121). The ‘pre-Cre’ PCR screening primers are 
listed in Table 2.3. After isolation of targeted neomycin resistant ‘pre-Cre’ clones, the 
cells were then treated with Cre-expressing recombinant adenovirus and single cell 
diluted to obtain ‘post-Cre’ neomycin sensitive clones. The ‘post-Cre’ PCR screening 
primers are listed in Table 2.4. Finally, all clones were subjected to a battery of Sanger 
sequencing and PCR confirmation experiments to ensure each clone was monoclonal and 
harbored the relevant BRCA1 alteration (Figures 2.3 and 2.4). The primers used in the 
confirmation experiments are shown in Tables 2.5-2.8. At least two clones were isolated 
for each of the engineered mutations listed in Figure 2.1A. In addition, wildtype rAAV 
gene targeting of both exon 5 and exon 11 was carried out to create at least one targeted 
wildtype control for each locus.  
ɣ-Irradiation Sensitivity Assay 
ɣ-irradiation sensitivity was determined by comparing sparsely seeded cells either treated 
with zero or six gray of radiation at a dose of approximately 3.63 gray/minute using a 
Xstrahl X-Ray irradiator. One day prior to ɣ-irradiation exposure, treated and untreated 
cells were plated in triplicate in 75 cm
2
 tissue culture flasks at densities of 800 cells and 
100 cells per flask, respectively. Following treatment, cells were maintained in fresh 
culture medium for 8-10 days until colonies were readily visible. For colony counting, 
cells were fixed and stained with 3.7% formaldehyde containing 0.2% (wt/vol) Crystal 
23 
 
violet (Sigma-Aldrich). Relative radio-sensitivity was defined as the inverse of fractional 
survival, as shown in Figure 2.6A. 
Fluorescent in situ Hybridization 
For all fluorescent in situ hybridization experiments, 1.0 x 10
5
 cells were plated in 8-well 
BD Falcon
TM
 glass chamber slides (Fisher Scientific) and grown exponentially for two 
days before being fixed with 10% neutral buffered formalin (Sigma-Aldrich). Following 
fixation, cells were washed in phosphate buffered saline (PBS) pH 7.4 (Life 
Technologies) and treated with a FISH pretreatment reagent kit (Abbott Molecular), 
according to the manufacturer’s recommendations. Pretreated, dehydrated slides were 
then probed simultaneously with Vysis LSI RET (Tel) SpectrumOrange and Vysis LSI 
MYC SpectrumGreen gene probes (Abbott Molecular). Following probe hybridization, 
slides were counterstained with 0.5 μg/mL 4,6-diamidino-2-phenylindole (DAPI) for 5 
minutes and mounted with Prolong Gold (Sigma-Aldrich and Life Technologies, 
respectively). Using a Nikon Eclipse 50i fluorescent microscope, at least 200 interphase 
cells were observed for gene copy number gains and losses. Percent copy number (CN) 
change from the mode was determined as the percentage of cells whose copy number 
deviated from the modal population for each gene probe. All derivatives harbored a MYC 
modal copy number of three and a RET modal copy number of two. To control for 
experimental variability across multiple experiments, each independent experiment 
included parental MCF-10A alongside each engineered derivative. Therefore, all data is 




To assess centrosome number in MCF-10A cells and all engineered derivatives, 1.0 x 10
5 
cells were plated in chamber slides and grown for two days under exponential growth 
conditions, before being fixed in cold methanol for 15 minutes at -20°C. Following 
fixation, cells were washed with cold acetone and treated for two hours with PBS 
containing 5% goat serum and 0.3% Triton X-100 (Sigma-Aldrich). A primary rabbit 
antibody against ɣ-tubulin was applied to the cells (Sigma-Aldrich) for one hour followed 
by a secondary goat anti-rabbit antibody conjugated to Alexa488 (Life Technologies) for 
20 minutes. The plasma membrane was stained with 5 μg/mL Texas Red
®
-X conjugated 
wheat germ agglutinin (WGA) for five minutes (Life Technologies) and the nucleus was 
counterstained with 0.5 μg/mL 4',6-diamidino-2-phenylindole (DAPI) for one minute 
(Sigma-Aldrich). The percentage of cells with greater than two centrosomes was 
determined by viewing at least 200 cells for each panel member using a Nikon Eclipse 
50i fluorescent microscope. Similar to the FISH analyses described above, each 
independent experiment included parental MCF-10A alongside each engineered 
derivative. Therefore, all data is reported as relative to parental MCF-10A.  
Ploidy Estimation 
Ploidy estimation was carried out by analyzing cells stained with the DNA intercalating 
agent, propidium iodide. Initially, 5.0 x 10
5
 cells were grown under exponential growth 
conditions for two days before being trypsinized, washed with cold PBS and fixed with 
70% cold ethanol. Fixed cells, stored for 1-7 days at -20°C, were then washed once with 
cold PBS before being stained with 40 μg/mL propidium iodide (Sigma-Aldrich) in the 
presence of 500 μg/mL DNase-free RNase A (Sigma-Aldrich) in 0.1% Triton X-100 
(Sigma-Aldrich) in PBS at 37°C for 15 minutes. For each isogenic derivative, at least 
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10,000 cells were analyzed using a FACSCalibur™ (BD Biosciences) for cell cycle 
distribution and polyploidy (>4n). To account for potential clonal artifacts, all data was 
normalized to parental MCF-10A and compared to targeted wild type controls. 
Statistical Considerations 
All statistical analyses were carried out using GraphPad Prism 6 software with P value 
significant level indicated using one or more asterisks: P ≤ 0.05 (*),P ≤ 0.01 (**) and P ≤ 
0.001 (***). Relative proliferation rates were analyzed by two-way ANOVA. Relative 
radiosensitivies were compared to both parental MCF-10A and controls using unpaired t-
tests. Results from the FISH, immunofluorescence and cell-cycle experiments were 
compared to control samples using unpaired t-tests. 
Results 
Engineering an Isogenic BRCA1 Panel 
To perform in vitro modeling of different BRCA1 carrier states, gene targeting 
experiments were conducted in the human non-tumorigenic breast epithelial cell line, 
MCF-10A (113). Figure 2.1 lists each of the engineered BRCA1 alleles, their recorded 
prevalence, clinical designation and respective locus. In each gene targeting experiment, 
at least two independently derived clones were isolated for each of the respective 
mutations/variants. In each of the described assays, the presented data represents means 
across 2 clones for each genetically distinct panel member. To control for clonal 
variation and/or possible effects caused by the gene targeting process, three independent 
targeted wild-type clones (two for exon 5 and one for exon 11) were established. For 
clarity, data generated for all three targeted wild-type control clones were grouped 
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together, as they all are expected to behave similarly. To act as positive controls in the 
characterization experiments, two unique pairs of BRCA1 truncating clones were used: 
our previously described BRCA1
185delAG
 cells and our newly established BRCA1
Ex2-3stop 
clones (described in the Materials & Methods).  
 For VUS modeling, we engineered five different VUS derivatives. The 
BRCA1
C64R
 derivative harbors a missense mutation located at the C-terminal end of 
BRCA1’s N-terminally located RING domain. The C64 residue is the last of several 
conserved zinc-coordinating residues located in the RING domain of BRCA1. Despite 
several studies describing the C64G missense mutation as deleterious, it remains unclear 
whether the C64R mutation is deleterious (70, 111, 122). The D67Y mutation lies 
adjacent to BRCA1’s RING domain and its clinical significance remains controversial. 
Currently, the BIC catalogs the D67Y mutation as a VUS, however, a large probabilistic 
study in 2007 classified it as benign (123). In contrast, some functional data exists 
suggesting that the D67Y may be hypomorphic, affecting BRCA1’s E3 ubiquitin ligase 
activity, and as a result, potentially centrosome dynamics and cisplatin sensitivity (108, 










map to a region purported to bind several important transcriptional 
factors, including c-MYC, TP53, RB and RAD50 (125–129). In addition, we engineered 
a benign variant located within the same region, BRCA1
I379M
, to better evaluate the 
validity of our model.  
 To evaluate potential functional differences between deleterious mutations, we 





RING domain mutation, BRCA1
C61G
, is the third most commonly reported deleterious 
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BRCA1 mutation, according to the BIC, and is thought to disrupt normal quaternary 
structure of the BRCA1/BARD1 heterodimer (37). The BRCA1
R71G
 mutation is a 
deleterious Spanish founder mutation that leads to aberrant splicing (130).  
Truncating BRCA1 Mutations Confer Slowed Proliferation 
First, we chose to study the proliferation rates of each of the BRCA1 panel members, 
since in our previous work we found that cells harboring the BRCA1
185delAG 
allele 
demonstrate slowed proliferation, as compared to parental MCF-10A cells. Mean relative 
growth rates are shown in Figure 2.5. In accord with previous observations, cells 




 cells, grew 
significantly slower than parental MCF-10A and controls. In contrast, cells harboring the 
deleterious missense mutation, BRCA1
R71G
, grew similar to controls. The BRCA1
C61G 
clones grew slightly slower than MCF-10A and controls. These results suggest that 
deleterious missense mutations may not be functionally synonymous with deleterious 






, appeared to 









mutations may have an effect on normal BRCA1 function. 
Lastly, the BRCA1
I379M 
benign variant cells grew marginally slower than parental MCF-
10A, but similar to its targeted wild-type control. 
Specific BRCA1 Genotypes Confer Sensitivity to ɣ-irradiation 
Next, we went on to assay each panel member’s sensitivity to ɣ-irradiation at 6 gray. 
Mean relative radio-sensitivities are shown in Figure 2.6B. Again, consistent with 
28 
 
previous work, cells harboring one truncating BRCA1 allele demonstrated a statistically 
significant increase in sensitivity to ionizing radiation. Notably, the BRCA1
185delAG
 cells 
demonstrated the largest radio-sensitivity across all deleterious clones, suggesting this 











clones also demonstrated increased sensitivity to ionizing radiation. Similar 
to the relative change in proliferation rates, the missense deleterious clones did not 
demonstrate as severe ɣ-irradiation sensitivity as the deleterious truncating clones, again 
suggesting a spectrum of functionality exists amongst deleterious alleles. The BRCA1
C64R 
VUS demonstrated radio-sensitivity similar to the BRCA1
C61G 
clones, suggesting this 
variant is deleterious. And lastly, the BRCA1
Q356R 
variant demonstrated a small increase 
in radio-sensitivity, suggesting this allele might also be hypomorphic. As expected, cell 
harboring the BRCA1
I379M 
benign variant were not more radiosensitive than controls. 
Chromosomal Instability (CIN) 
To assess chromosomal instability (CIN), we chose to use the conventional method of 
fluorescent in situ hybridization (FISH). FISH permits investigators to not only observe a 
cell’s genomic state (i.e. copy number), but also the frequency of copy number deviation 
across many cells within a given cell population; or CIN (131). For all panel members, 
we evaluated CIN using two gene probes (MYC and RET). CIN estimates are reported as 
the average relative copy number deviation for each probe and are shown in Figure 2.7. 
As expected, cells harboring a truncating BRCA1 allele demonstrated an increase in CIN 





, also demonstrated CIN, but only for the RET gene probe. 
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 VUS were the only other derivatives 
demonstrating statistically significant CIN. Consistent with the irradiation experiments, 
these results suggest that the BRCA1
C64R
 VUS is a deleterious variant. Although the 
BRCA1
D67Y 
cells did demonstrate statistically significant CIN, the difference from 
controls was relatively small. In accord with other work, these results suggest that the 
BRCA1
D67Y 
allele may have hypomorphic properties. As expected, cell harboring the 
BRCA1
I379M 
variant did not demonstrate CIN, further corroborating its neutral effect on 
protein function. 
Cell-Cycle Analysis Reveals an Increased Fraction of Polyploid Cells 
During the FISH experiments described above, we also observed a striking trend; many 
(but not all) of the clones demonstrating CIN appeared to display a small but observable 
fraction of cells with >2 times the modal copy number for one or both gene probes, as 
shown in Figure 2.8A. This led us to perform cell cycle analysis for ploidy estimation. 
Figure 2.8B shows the average percentage of cells with >4n for each derivative 





, both demonstrated a larger fraction of polyploid cells, but 
the truncating mutants did not. Again, these results suggest that not all deleterious 





, appeared to demonstrate a statistically significant increase in polyploid 
events. These results suggest that the BRCA1
D67Y 
variant does abrogate normal BRCA1 
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function. As expected, the  BRCA1
I379M 
derivatives demonstrated results very similar to 
controls, suggesting this neutral variant has no impact on normal BRCA1 function. 
Centrosome Amplification 
Lastly, BRCA1 has been implicated in the regulation of centrosome duplication, whereby 
inhibition of BRCA1 or loss of function leads to an increase in cell centrosome number 
(74). Interestingly, a recent study showed that normal breast tissue from deleterious 
BRCA1 carriers displays increased centrosome number, relative to controls (61). The 
abnormal centrosome dynamics observed in BRCA1-altered cells appears to be linked to 





 mutations localize (55, 74, 108). 
 Therefore, to study whether our isogenic panel members also demonstrate an 
increase in overall centrosome number, we performed immunofluorescent staining of ɣ-
tubulin, a major centrosomal core protein, to quantify cellular centrosomes. Relative 
centrosome amplification results with representative images are shown in Figure 2.9. In 
line with the observations made by Martins et al., we observed an increase in centrosome 









derivatives. Unexpectedly, the BRCA1
C61G 
cells did not demonstrate a 
significant increase in centrosome number relative to parental MCF-10A or controls. It is 
possible that truncating BRCA1 mutations have a larger effect on centrosome number 
than BRCA1 RING mutants. This is consistent with the similar results observed for the 
BRCA1
C64R
 variant. However, the BRCA1
C64R 
variant did demonstrate statistically 
significant change. Nonetheless, these results further suggest that the BRCA1
C64R
 variant 
is deleterious. The BRCA1
D67Y
 variant demonstrated the highest number of multi-polar 
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mitoses among all panel members, again suggesting this variant does influence function.  
Interestingly, the centrosome amplification observed for the BRCA1
D67Y
 cells appears to 
correlate with the fraction of polyploidy cells discussed above.  

















Table 2.1: Homology Arm Cloning Primers 
Locus Homology Arm Forward/Reverse 






















Table 2.2: Mutagenesis Primers 





























































Table 2.4: Post-Cre Screening Primers 
Locus Forward/Reverse 


















Table 2.5: PCR Primers Across loxP Scar 
Locus Forward/Reverse 










Table 2.6: Targeted Allele Sequencing Primers  



























Table 2.7: Bi-Allelic Sequencing Primers  











Table 2.8: cDNA Sequencing Primers  























Table 2.9: Isogenic Panel Summary 
ID Radiosensitive 









Ex2-3Stop + + + - + N/A 
185delAG + + + - + Deleterious 
R71G + - + + + Deleterious 
C61G + - + + - Deleterious 
C64R + - + - + VUS 
D67Y - - + + + VUS 
S316G - - - + - VUS 
Q356R + - - - - VUS 
L246V - - - - - VUS 
















































Loss-of-heterozygosity (LOH) analysis of resected tumor tissue has been helpful for 
classifying particular BRCA VUS (105, 132–134). Yet several technical hurdles exist that 
hinder archival tissue-based studies. In particular, formalin fixation leads to a high degree 
of tissue damage, yielding a limited amount of usable DNA molecules for downstream 
applications. Moreover, contaminating normal DNA present within formalin fixed 
paraffin embedded (FFPE) tumor DNA preparations can hinder many genetic analyses. 
Additionally, techniques such as fluorescence in situ hybridization (FISH) have intrinsic 
shortcomings that make analysis of archival tissue challenging. Specifically, FISH is 
subjective, prone to inter-observer variability, has limited sensitivity, can be technically 
difficult, time consuming, and cannot identify certain genomic alterations, such as loss 
with duplication (135). To circumvent some of these challenges and facilitate future LOH 
studies, droplet digital PCR (ddPCR) was used to study genomic DNA derived from 
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archival tumor tissues from two members of a cancer prone family harboring a BRCA2 
VUS.  
Materials & Methods 
Combined Clinical History 
A 46-year-old woman of non-Ashkenazi ancestry and a family history of cancer, 
presented to the clinic for genetic counseling and testing for hereditary breast and ovarian 
cancer syndromes. Three years prior to her presentation, the proband was diagnosed with 
a grade II invasive ductal carcinoma (IDC) of the right breast with ductal carcinoma in 





), and did not over-express the human epidermal growth factor 
receptor 2 (HER2
-
). The proband’s mother was also diagnosed with a grade I IDC of the 
left breast with DCIS at the age of 76. Following a consultation with the proband, she and 
her mother were encouraged to pursue germline testing for mutations/alterations of the 
BRCA1 and BRCA2 genes. Clinical genetic testing for the proband and her mother 
revealed the presence of a BRCA2
 
variant of uncertain clinical significance (c.6966G>T; 
M2322I).  
Tissue Processing, Nucleic Acid Preparation & Sanger Sequencing 
Buccal and FFPE derived genomic DNA (gDNA) was isolated using 
QIAamp® DNA Blood Mini and QIAamp® FFPE tissue kits, respectively (Qiagen, 
Valencia, CA). Genomic DNA was isolated from FFPE tissue using standard 
protocols. Briefly, H&E stained histology slides were examined by a pathologist to 
identify areas of at least 70% breast carcinoma cells and adjacent benign lobular 
epithelial cells with 0% tumor cells greater than 10mm from any invasive component, 
48 
 
hereafter termed FFPE tumor and FFPE normal, respectively. Five-micron thick 
unstained slides were deparaffinized and identified regions of interest were 
macrodissected using the Zymo pen and Pinpoint solution (Zymo Research, Irvine, 
CA), per the manufacturer’s protocol. Sanger sequencing of gDNA was carried out 
following PCR amplification of respective loci using Phusion® High-Fidelity DNA 
Polymerase (New England BioLabs, Ipswich MA). PCR and nested sequencing 
primers for each locus described herein are listed in Table 3.1. 
Droplet Digital PCR Experiments 
All droplet digital PCR experiments were carried out using the QX100™ Droplet 
Digital PCR System according to the manufacturer’s protocols (Bio-Rad, Hercules, CA), 
as previously described (136). Droplet Digital PCR primers were purchased from 
Integrated DNA Technologies (Coralville, IA) and fluorescently labeled TaqMan® 
probes were purchased through Life Technologies (Carlsbad, CA). Primer and probe 
sequences are shown in Table 3.2. Prior to analysis of patient DNA samples, optimized 
thermo-cycling conditions were determined for allele-specific binding of the fluorescent 
probes by initially cloning 381 base pairs of genomic sequence encompassing BRCA2 
exon 13 (both the wild-type and VUS alleles) with flanking intronic sequence into a high-
copy bacterial plasmid. The temperature range of 56-58°C provided strong fluorescent 
signals and yielded no probe cross-reactivity. Therefore, the manufacturers’ 
recommended thermo-cycling protocol with a 58°C annealing/extension step were carried 
out. Figure 3.1 shows experimental data from a representative ddPCR titration 
experiment demonstrating 100% probe specificity using linear plasmid DNA as PCR 
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template. All data analysis was performed using the accompanying platform software, 
QuantaSoft (Bio-Rad), with all reported values calculated using Poisson statistics.  
Targeted Next-Generation DNA Sequencing 
The proband’s archival tissue derived genomic DNA (both tumor and surrounding 
normal) was subjected to targeted next-generation DNA sequencing using a custom 484 
cancer gene panel. Targeted coding exon enrichment was carried out using Agilent’s 
SureSelect technology and DNA sequencing was performed on an Illumina HiSeq 2000 
platform. Resultant data was aligned to human genome 19 using BWA 0.6.1 (137) and 
variants were called using GATK 1.4 (138). 
Results  
To confirm the presence of the BRCA2
M2322I
 (c.6966G>T) variant in the two 
affected family members, exon 13 of BRCA2 from buccal cell derived gDNA was 
sequenced. Consistent with previous genetic testing, both individuals diagnosed with 
cancer harbored the VUS. In addition, a heterozygous single nucleotide polymorphism 
(SNP) located within exon 11 of BRCA2, rs543304, was identified for the proband and 
her mother. The rs543304 SNP is located in exon 11 approximately 8.7 kilobases 
upstream on gDNA from the VUS, as illustrated in Figure 3.2a. Sanger sequencing traces 
derived from buccal cell gDNA depicting the VUS and rs543304 SNP are shown in 
Figure 3.2b. Next, gDNA from FFPE tissue blocks for the proband and her mother was 
purified to perform LOH and sequencing analysis on macrodissected tumor and adjacent 
normal breast tissue. Using Sanger sequencing for both the proband and her mother the 
rs543304 SNP was found to be heterozygous (Figure 3.2c). However, as seen in the 
sequencing traces in Figure 3.2c, there was a high degree of variability in Sanger 
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sequencing results for the VUS locus. Both tumor samples appeared to have a 1:1 ratio of 
wild type to VUS alleles. In contrast, the proband’s normal adjacent tissue, appeared to 
have a 2:1 wild type to VUS allelic ratio, while the mother’s normal tissue seemingly 
contained a 1:2 wild type to VUS ratio. This type of variability in PCR sequencing is not 
uncommon with the use of FFPE derived DNA, particularly when using minute quantities 
of DNA. Therefore, in order to confirm that our tumor and normal samples were not 
inadvertently switched, since allelic ratios are more often changed in tumors, the DNA 
used for these analyses were used for candidate gene sequencing to identify somatic 
mutations. First, exons 9 and 20 of PIK3CA and all coding exons of TP53 were 
sequenced, as these genes are frequently mutated in breast cancers (139, 140). Initial 
sequencing results revealed a heterozygous somatic mutation in exon 20 of PIK3CA 
(c.3140A>T; H1047L) in the mother’s tumor gDNA, as shown in Figure 3.3a. The 
proband’s DNA preparations exhibited no PIK3CA mutations and neither patient 
demonstrated a TP53 mutation by Sanger sequencing. Since no somatic mutations were 
identified for the proband for PIK3CA or TP53, the tumor and adjacent normal genomic 
DNA was used for targeted next generation sequencing with a custom 484 cancer gene 
panel. Unique somatic alterations found only in the proband’s tumor were identified and 
are shown in Figure 3.3b.  
The identification of somatic mutations in the tumor samples strongly suggested 
that the identity of the samples is correct and they samples were not mistakenly switched. 
Therefore, the results with PCR and Sanger sequencing underscored the difficulty of 
determining allelic ratios and LOH using FFPE derived DNA. To more accurately 
measure the BRCA2 allelic ratios, the relatively new technology of ddPCR was used to 
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perform LOH analyses. Briefly, ddPCR is carried out through the creation of nanoliter 
droplets acting as parallel single molecule PCR reactions (Figure 3.4a) (136). The 
identity of the DNA molecules within each droplet can then be resolved using 
conventional dual labeled fluorescent oligonucleotide probes. Following end-point PCR 
on a standard thermo-cycler, all droplets are then counted using a fluorescent droplet 
reader (Figure 3.4b). It is reasonable to hypothesize that ddPCR would be well suited for 
LOH analysis of FFPE derived DNA for a number of reasons. First, it requires low 
amounts of input DNA with very short PCR amplicon sizes (<100 bp). Second, ddPCR 
uses dual labeled probes that are capable of reliably discriminating between single base 
pair changes, such as SNPs and mutations. Third, ddPCR has the capacity to easily and 
accurately determine differences in copy number below 2-fold, which is the lower limit 
of reliable detection using conventional quantitative real time PCR (qPCR). Therefore, 
this approach was used to effectively count the number of BRCA2 alleles present within 
the patients’ DNA samples using allele specific probes. By comparing the number of 
BRCA2 alleles present within our patients’ samples it is possible to simultaneously assess 
LOH and quantify contaminating normal DNA, as illustrated in Figure 3.4b. Using 
conventional allele-specific fluorescent probes, differing by only one nucleotide at 
BRCA2 c.6966G/T, the BRCA2 allelic ratios were quantified within the normal and tumor 
FFPE gDNA for both individuals. As shown in Figure 3.5a, the allelic ratios (wild 
type:VUS) were determined to be approximately one in all tissue samples assayed. 
Absolute percentages of wild type to VUS alleles are shown in Figure 3.5b. 
Representative 2D droplet reading plots for each patient sample are shown in Figure 6. 
Overall, these data clearly show no evidence of LOH in either individual’s tumor or 
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normal sample, and importantly underscore the inability of conventional PCR-Sanger 



















Table 3.1: Sanger sequencing primers 




































Table 3.2: ddPCR Primer and Probe Sequences 
Primer/Probe  Sequence 




BRCA2 WT Probe  5’-[VIC]-catgatgCataaacaatc-[MGB] 






























BRCA VUS pose a formidable challenge to hereditary breast and ovarian cancer 
prevention. Approximately half of the nearly 4,000 cataloged BRCA alleles in the BIC are 
currently designated as VUS. To combat this ongoing problem many studies have been 
developed towards classifying VUS (103–105, 141). Arguably the most effective 
approaches utilize a number of clinically relevant features to calculate a likelihood score 
that a given VUS is deleterious. Often, however, the number of reported carriers for a 
given VUS is very small, sometimes consisting of only one individual. These small 
sample sizes coupled with the incomplete penetrance of BRCA-linked disease and the 
high incidence of sporadic breast cancer leads to insignificant statistical predictions. 
Therefore, investigators have turned to other modeling approaches, namely in silico 
analysis and direct functional testing. 
Isogenic Cell Modeling of BRCA1 Alleles 
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Isogenic cell modeling of BRCA1 alleles, distinct from other in vitro functional 
tests, boasts several advantages that make it an attractive alternative to prior BRCA1 
modeling approaches. First, isogenic modeling in non-cancerous human breast epithelial 
cells permits investigators to evaluate BRCA1 function within the appropriate cellular 
context; non-cancerous human breast cells. Many of the prior studies have not done so, 
where they studied BRCA1 function in either human breast cancer cell lines or mouse 
embryonic stem cells. Secondly, isogenic cell modeling facilitates BRCA1 study at 
appropriate dosages via the control of the endogenous machinery. Prior studies have used 
exogenously expressed human BRCA1 cDNA, and as a result studied BRCA1 function at 
artificially high levels. Thirdly, since isogenic modeling can be carried out in different 
genetically stable cell lines, it permits the interrogation of BRCA1 function under 
genetically defined conditions, thereby potentially providing new insight into the effects 
of genetic modifiers. Lastly, this methodology also possesses the advantage of 
expandability. As a clearer understanding of BRCA1 function evolves, additional 
characterizing assays may be adapted for in vitro study. 
Here we used isogenic modeling to evaluate functional differences between nine 
clinically important BRCA1 alleles, including three deleterious, five VUS and one benign 
variant. Several conclusions can be made from experiments described herein. First, it 
seems that not all BRCA1 deleterious mutations confer the same level of functional loss 
in vitro. That is, it appears that truncating BRCA1 mutations lead to a higher level of 
sensitivity to ionizing radiation and genomic instability, as compared to other cancer 
causing BRCA1 missense mutations. Whether these functional differences influence 
disease penetrance remains to be determined. Secondly, our data suggest isogenic cell 
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modeling may be useful for providing functional evidence for VUS classification efforts, 
where here we describe the functional effects of five VUS. Characterization of the C64R 
variant suggests this mutation is at least equally as deleterious as the C61G mutation, 
since cells harboring this mutation were sensitive to ionizing radiation and demonstrated 
increased genomic instability and centrosome amplification. Functional characterization 
of the D67Y mutation suggests it may be hypomorphic. As this mutation has previously 
been predicted to be benign, it may be that certain hypomorphs do not increase cancer 
risk in carriers. However, this also remains to be seen. Similarly, the cells harboring the 
S316G and Q356R only scored in one assay each, suggesting both may have 
hypomorphic properties. Despite the suppressed growth rate observed for cells harboring 
the L246V VUS, this variant did not demonstrate an appreciable difference from controls 
in the other assays, suggesting this variant may be benign. Nonetheless, further work is 
needed to determine if our in vitro model accurately reflects in vivo phenomena, and 
ultimately relative disease risk.  
 Like most models, the approach taken here does have some caveats. First, only 
one breast cell line, MCF-10A, was used to generate our BRCA1 panel. It is possible that 
pre-existing genetic modifiers present within the MCF-10A genome influence the effects 
observed for the engineered mutations. To circumvent this problem, it would be 
necessary for future studies to employ other human non-tumorigenic breast cell lines, 
such as the hTERT immortalized breast epithelial cell line (hTERT-IMEC) we utilized in 
our previous isogenic studies with the BRCA1
185delAG 
alteration (62). Another potential 
shortcoming with the approach taken here resides in the employed gene targeting method, 
rAAV. rAAV-mediated gene-targeting is far from ideal, where it can be laborious, leaves 
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exogenous sequence following targeting (i.e. loxP scar DNA) and is susceptible to 
random integration of the targeting construct. Newer, alternative gene targeting methods, 
such as the CRISPR system, may overcome these problems (142). The very high 
targeting efficiency of the CRISPR system make it ideal for fast, selection free gene 
targeting. Finally, the number of deleterious and benign mutations engineered in this 
study is too small to make broader conclusions about the clinical applicability of isogenic 
modeling for BRCA1 allele risk assessment. Further work is needed to translate our in 
vitro BRCA1 haploinsufficiency observations towards clinical utility.  
 In accordance with previous work, and the work of others, we present further 
evidence for the hypothesis that mammary epithelial cells harboring a deleterious BRCA1 
allele are haploinsufficient for BRCA1. The results from our -irradiation experiments 
may have important implications for the current screening mammography paradigm in 
BRCA carriers. Consistent with previous studies showing that X-ray screening in BRCA 
carriers may increase cancer risk (143), the cells harboring a deleterious allele 
demonstrated increased radio-sensitivity. Presumably the increase in sensitivity is due to 
the cell’s inability to repair DNA damage caused by the ionizing radiation. Therefore, 
MRI may be a safer alternative for screening within this cohort (144). In summary 
isogenic modeling of BRCA1 alleles is useful for study of disease causing alleles and 
alleles not clearly linked to cancer. 
ddPCR Mediated LOH Analysis  
LOH analysis, in combination with other methods, is useful in classifying 
uncertain BRCA variants. Although loss of the wild-type allele in tumor tissues provides 
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strong evidence for a deleterious germline mutation, it should be noted that absence of 
LOH cannot be used as a definitive criterion, since other mechanisms of inactivation of 
the wild-type allele exist. This would include epigenetic silencing as well as a de novo 
inactivating mutation within the wild-type allele. Nonetheless, given that loss of the 
second allele is an accepted common mechanism of carcinogenesis mediated by tumor 
suppressor genes in familial cancer syndromes, the studies described here have great 
potential for definitively assessing LOH and helping to ascribe a functional significance 
to germline VUS and deleterious mutations. 
 The arrival of commercially available digital PCR platforms has the potential to 
dramatically alter the speed and sensitivity of many molecular biology assays commonly 
used in the clinic. Others have shown that ddPCR can accurately determine both copy 
number changes and expression of critical oncogenes using patient samples (145, 146). 
This approach may prove to be a more objective and accurate measure for determining 
oncogene amplification and overexpression in cancer patients. Droplet digital PCR is 
especially useful for analysis of FFPE derived gDNA, since it relies on short DNA 
fragments and FFPE gDNA is generally highly fragmented. Moreover, since ddPCR 
queries individual DNA molecules, this approach should prove useful in several assays 
including determining the fractional abundance of somatic mutations within 
heterogeneous tumor tissue specimens, validation of somatic mutations identified using 
whole genome sequencing that are below the limit of detection by Sanger sequencing, 
and as demonstrated here, determining the allelic fraction of a given gene for LOH 
analysis. Although in principle, next generation sequencing using a targeted gene capture 
approach could also be used for LOH and copy number analysis, ddPCR offers 
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significant advantages including a much faster and cost efficient platform, need for less 
input DNA, superior sensitivity, no artifactual errors inherent with next generation 
sequencing, and no requirement for a bioinformatics pipeline for variant calling. To our 
knowledge, this is the first report demonstrating the utility of using ddPCR for accurately 
assessing allelic ratios via SNPs in FFPE tumor samples. This approach should greatly 
facilitate not only BRCA VUS LOH studies, but studies for other variants of genes 
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